NCT07227402 2026-04-17
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
64 trialsNCT07405164 2026-04-17
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT07197580 2026-04-01
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT03815643 2026-03-31
Avelumab Program Rollover Study
EMD Serono
Phase 3 Active not recruiting
NCT07489495 2026-03-24
LITESPARK-034
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT04338269 2026-03-19
CONTACT-03
Hoffmann-La Roche
Phase 3 Terminated
NCT03142334 2026-03-10
KEYNOTE-564
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07000149 2026-03-10
eVOLVE-RCC02
AstraZeneca
Phase 3 Active not recruiting
NCT04586231 2026-03-05
MK-6482-011
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03873402 2026-01-21
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05899049 2025-11-10
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04810078 2025-10-09
CheckMate-67T
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03937219 2025-09-10
COSMIC-313
Exelixis
Phase 3 Active not recruiting
NCT04987203 2025-08-22
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT05239728 2025-08-14
MK-6482-022
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT03260894 2025-07-29
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT02231749 2025-06-26
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT03141177 2025-06-06
CheckMate 9ER
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05043090 2025-05-08
SAMETA
AstraZeneca
Phase 3 Active not recruiting
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03592472 2025-04-13
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Xynomic Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT06750419 2024-12-27
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT03138512 2024-12-18
CheckMate 914
Bristol-Myers Squibb
Phase 3 Completed
NCT04736706 2024-11-18
MK-6482-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03849118 2024-05-17
89ZR-TLX250
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Completed
NCT03024996 2023-08-03
IMmotion010
Hoffmann-La Roche
Phase 3 Terminated
NCT02627963 2023-07-18
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
AVEO Pharmaceuticals, Inc.
Phase 3 Completed
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT02420821 2023-01-30
IMmotion151
Hoffmann-La Roche
Phase 3 Completed
NCT01668784 2022-08-09
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Bristol-Myers Squibb
Phase 3 Completed
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT01235962 2020-11-23
PROTECT
Novartis
Phase 3 Completed
NCT00397345 2020-10-19
TroVax Renal Immunotherapy Survival Trial
Oxford BioMedica
Phase 3 Completed
NCT01599754 2019-09-20
ATLAS
SFJ Pharmaceuticals, Inc.
Phase 3 Terminated
NCT00087022 2018-11-27
ARISER
Heidelberg Pharma AG
Phase 3 Completed
NCT03693573 2018-11-15
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
Hoffmann-La Roche
Phase 3 Withdrawn
NCT00606632 2018-10-02
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Heidelberg Pharma AG
Phase 3 Completed
NCT01582672 2018-06-14
ADAPT
Argos Therapeutics
Phase 3 Terminated
NCT01762592 2017-12-22
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
Heidelberg Pharma AG
Phase 3 Withdrawn
NCT01265901 2017-10-12
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Immatics Biotechnologies GmbH
Phase 3 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT00061178 2016-10-19
Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
Genentech, Inc.
Phase 3 Withdrawn
NCT00738530 2016-06-23
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Hoffmann-La Roche
Phase 3 Completed
NCT00631371 2016-04-27
INTORACT
Pfizer
Phase 3 Completed
NCT00334282 2016-02-05
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
GlaxoSmithKline
Phase 3 Completed